Belite Bio, Inc (BLTE): Price and Financial Metrics
BLTE Price/Volume Stats
| Current price | $38.00 | 52-week high | $48.60 |
| Prev. close | $37.27 | 52-week low | $11.00 |
| Day low | $36.01 | Volume | 16,000 |
| Day high | $38.49 | Avg. volume | 57,906 |
| 50-day MA | $41.70 | Dividend yield | N/A |
| 200-day MA | $36.80 | Market Cap | 1.11B |
BLTE Stock Price Chart Interactive Chart >
Belite Bio, Inc (BLTE) Company Bio
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Latest BLTE News From Around the Web
Below are the latest news stories about BELITE BIO INC that investors may wish to consider to help them evaluate BLTE as an investment opportunity.
Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor ConferenceSAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will be participating at the Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference to be held Thursday, December 7, 2023, at the New York Athletic Club in New York City. To schedule a one-on-one me |
Belite Bio to Participate in the BTIG Ophthalmology DaySAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that management will participate in a fireside chat at the BTIG Ophthalmology Day on Monday, November 27, 2023, at 3:00 p.m. ET. The Belite management team will be participating in one-on-one meetings at the event. Investor |
Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial ResultsComparison of the 24-month DDAF lesion growth between Tinlarebant-treated subjects and ProgStar participants Comparison of the 24-month DDAF lesion growth between Tinlarebant-treated subjects and ProgStar participants Comparison between Tinlarebant-treated subjects and ProgStar participants Comparison between Tinlarebant-treated subjects and ProgStar participants Completed enrollment in pivotal Phase 3 “DRAGON” trial for Tinlarebant in adolescent Stargardt disease (“STGD1”) with 104 subjects enr |
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online ViewingCompany Executives Share Vision and Answer Questions at VirtualInvestorConferences.comNEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Deutsche Bank Depositary Receipts Virtual Investor Conference (“dbVIC”) held on November 8th and 9th are now available for online viewing. REGISTER NOW AT: https://bit.ly/3SyFOaq The company presentations will be available 24/7 for 90 days. Nove |
Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial ResultsSAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, November 14, 2023, at 4:30 p.m. Eastern Time to discuss the Company’s financial results for the third quarter ended September 30, 2023, and provide a general business update. Webcast I |
BLTE Price Returns
| 1-mo | -4.83% |
| 3-mo | -16.67% |
| 6-mo | 2.01% |
| 1-year | 31.49% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -16.94% |
| 2023 | 51.77% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...